GlassScriptPhysician profile
Joseph Masiello
NPI 1861285413
$3,100.32
in general payments reported to CMS, 2019-2025
16 companies · $3,100 in 2025
The $3,100 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,907 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.98 |
| Education | $193.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $574.20 | 2025 | Tremfya |
| Leo Pharma INC. | $518.92 | 2025 | Anzupgo, Adbry |
| Abbvie INC. | $409.80 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $250.64 | 2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $229.01 | 2025 | Ilumya, Winlevi |
| Galderma Laboratories, L.P. | $211.85 | 2025 | Nemluvio, Aklief |
| Genzyme Corporation | $202.53 | 2025 | |
| Incyte Corporation | $201.01 | 2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $159.36 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $148.26 | 2025 | |
| Amgen INC. | $69.12 | 2025 | Otezla |
| Lnhc, INC | $53.62 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.69 | 2025 | Spevigo |
| Teva Pharmaceuticals USA, INC. | $20.16 | 2025 | |
| Organon LLC | $15.32 | 2025 | Hadlima |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14.83 | 2025 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Masiello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.